← FDA DRUG APPROVALS

FDA ANDA · ANDA202016

MELAMISA

Sponsor: NOVAST LABS

APPLICATION
ANDA202016
TYPE
ANDA
ORIGINAL APPROVAL
2016-01-26
LATEST ACTION
2025-03-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

MELAMISAPrescription
DROSPIRENONE 3MG, ETHINYL ESTRADIOL 0.02MG · TABLET · ORAL

Approval history

2025-03-21Labeling · Supplement 7 · standardAP
2025-03-21Labeling · Supplement 1 · standardAP
2025-03-21Labeling · Supplement 8 · standardAP
2016-01-26OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →